Melissa Badamo

DocwireNews

Crizanlizumab is safe and well-tolerated in patients with sickle cell disease, according to results from the STAND trial published in The Lancet Haematology.Results from the SUSTAIN study previously demonstrated a lower rate of vaso-occlusive crises in patients treated with 5.0 mg/kg crizanlizumab versus placebo. In the randomized, double-blind, phase 3 STAND study, Miguel R Abboud, MD, American University of Beirut Medical Center, and colleagues further evaluated the safety and efficacy of two doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) compared with placebo.Of the 252 patients included in the study, 85 were randomized to the crizanlizumab 7.5 mg/kg group, 84 to the crizanlizumab 5.0 mg/kg group, and 83 to the placebo group. The primary endpoint was the annualized rate of vaso-occlusive crises that led to a healthcare visit over the first year of treatment. The secondary objective was safety.The adjusted annualized rate of vaso-occlusive crises was 2.49 (95% CI, 1.90&ndash;3.26) in the crizanlizumab 5.0 mg/kg group, 2.04 (1.56&ndash;2.65) in the 7.5 mg/kg group, and 2.30 (1.75&ndash;3.01) in the placebo group. The rate of adjusted annualized rates of vaso-occlusive crises leading to healthcare visits was 1.08 (95% CI 0.76&ndash;1.55, P&gt;0.999) for 5.0 mg/kg and 0.89 (0.62&ndash;1.27, P&gt;0.999) for 7.5 mg/kg vs placebo.The researchers noted that the safety profile was consistent among the three treatment groups. Grade 3 or higher adverse events (AEs) occurred in 27 (32%) patients in the placebo group, 32 (39%) in the crizanlizumab 7.5 mg/kg group, and 47 (56%) in the crizanlizumab 5.0 mg/kg group. The rates of serious AEs followed a similar trend across treatment groups, occurring in 26 (31%) of patients in the placebo group, 22 (27%) in the crizanlizumab 7.5 mg/kg group, and 35 (42%) in the crizanlizumab 5.0 mg/kg group.While the rates of AEs were lower in the placebo and crizanlizumab 7.5 mg/kg groups than the crizanlizumab 5.0 mg/kg group, there were no differences in efficacy between crizanlizumab and placebo.ReferenceAbboud MR, et al. Lancet Haematol. 2025;12(4):e248-e257. doi:<a href="https://pubmed.ncbi.nlm.nih.gov/40088922/">10.1016/S2352-3026(24)00384-3</a>

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Phase 3 STAND Trial Supports Safety and Tolerability of Crizanlizumab in SCD

Sickle Cell Disease

Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.

Phase 3 STAND Trial Supports Safety and Tolerability of Crizanlizumab in Sickle Cell Disease

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe